{"entity":{"id":"paper-pharos-encorafenib-binimetinib-riely-jco-2023","kind":"paper","name":"PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer","aka":[],"tldr":"A second BRAF and MEK inhibitor pair, encorafenib plus binimetinib, shrank tumours in three quarters of untreated and nearly half of previously treated patients with BRAF V600E lung cancer, giving a better-tolerated alternative to dabrafenib-trametinib.","summary":"Phase 2 study of 98 patients with BRAF V600E-mutant metastatic non-small-cell lung cancer, 59 treatment-naive and 39 previously treated, given encorafenib plus binimetinib.\n\nObjective response was 75 percent in treatment-naive and 46 percent in previously treated patients, with median duration of response not reached and 16.7 months respectively; pyrexia was less common than with dabrafenib-trametinib.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2023","url":"https://doi.org/10.1200/JCO.23.00774"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37270692/"}],"tags":[],"related":[],"cancers":["braf-v600e-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["binimetinib","encorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["pharos"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2023,"doi":"10.1200/JCO.23.00774","pmid":"37270692","authors":"Riely GJ, Smit EF, Ahn MJ, et al.","paperType":"observational","findings":["Objective response 75 percent (treatment-naive) and 46 percent (previously treated).","Median duration of response 16.7 months in previously treated patients."],"whatItMeans":"Encorafenib-binimetinib is approved for BRAF V600E lung cancer and offers a second targeted option, particularly for patients troubled by fever on dabrafenib-trametinib.","caveats":["Single-arm; no head-to-head comparison with dabrafenib-trametinib."],"changedPractice":true,"participants":98},"route":"/key-papers/paper-pharos-encorafenib-binimetinib-riely-jco-2023/","neighbours":{"cancer":[{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/"}],"drug":[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"}],"trial":[{"id":"pharos","kind":"trial","name":"PHAROS","route":"/trials/pharos/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}